finance
Arcera and Fosun Pharma Sign MoU to Boost Innovation in China and UAE
Arcera and Fosun Pharma have executed a memorandum of understanding in Shanghai, China. The agreement, signed by key executives, aligns with strategic partnerships between China and the UAE. It aims to create pathways for innovation and market access in both nations.
finance.yahoo.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Arcera and Fosun Pharma executed a memorandum of understanding in Shanghai, China, Benzinga reported. The agreement was signed by Sunil Bhilotra, Chief Investment Officer of Arcera, and Xingli Wang, Co-President of Fosun Pharma and CEO of Innovative Medicines Division.
She also acts as the CEO of the Innovative Medicines Division based in Shanghai, China. The MoU aligns with the Comprehensive Strategic Partnership between the People's Republic of China and the UAE.
It also supports Abu Dhabi's Healthcare Life Sciences Vision 2030 objectives. These alignments provide a framework for the collaboration between the two entities. Through the MoU, pathways for innovation and market access are created in both China and the UAE.
This development fosters opportunities for advancements in healthcare and life sciences sectors. The agreement marks a step toward enhanced bilateral cooperation in these fields.
